UTHR
United Therapeutics Corporation
October 2, 2026 · intraday
- Rarity
- 1.80
- Peak move
- −5.17%
- Float cap
- $24.1B
United Therapeutics Corporation is a public benefit corporation that develops and commercializes therapies for people with serious diseases and unmet medical needs. It markets and sells treatments for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, including Tyvaso, Remodulin, Orenitram, and Adcirca, as well as Unituxin for high-risk neuroblastoma. Its products are sold primarily in the United States, with some sales in select international markets.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
16 events · 4 from SEC or newswire · 0 timed with the moveinsider_saleUnited Therapeutics Chairperson and CEO Martine A. Rothblatt sold 1,920 shares on September 30, 2026 at prices between $547.29 and $554.70, worth about $1.06 million, under a pre-arranged 10b5-1 trading plan adopted November 7, 2025, retaining about 668,728 shares.
insider_saleChairperson & CEO Martine A. Rothblatt exercised options for 9,500 shares at $117.76 and sold them on September 30, 2026 at prices from $476.14 to $554.70, a sale of about $3.9 million under a Rule 10b5-1 plan adopted November 7, 2025, leaving 324,443 shares held; she also sold 9,500 shares on September 29, 2026 at $472.05-$486.77 and 1,920 shares at $547.29-$554.70.
- Key event
insider_saleDirector and officer Martine Rothblatt filed notice to sell 209,000 shares of United Therapeutics common stock, valued at about $113.3 million at an average price of $541.89, under a 10b5-1 plan, after selling 598,500 shares in the past three months.
SEC144 0001950047-26-009982 insider_saleEVP & General Counsel Paul A. Mahon exercised options for 8,300 shares at $146.03 and sold all of them on October 1, 2026 at prices from $558.30 to $573.15, about $4.69 million at an average price of $564.95, under a Rule 10b5-1 plan adopted August 11, 2025, leaving 45,172 shares held; a Form 144 notice valued the shares at about $4.7 million.
- Key event
analyst_ratingBTIG upgraded United Therapeutics to Buy from Neutral with a $728 price target, citing the '327 patent ruling as a significant impediment to Liquidia's Yutrepia in PH-ILD and IPF optionality with an April 2027 PDUFA date.
- Key event
analyst_ratingBofA Securities lowered its price target on United Therapeutics to $559 from $613, maintaining a Neutral rating, after the company said it would no longer reaffirm its prior Tyvaso sales guidance.
insider_saleA United Therapeutics insider sold shares worth $1,056,425 in a transaction disclosed in a recent SEC filing.
insider_saleChairperson & CEO Martine A. Rothblatt sold 9,500 shares of United Therapeutics on September 29, 2026 at prices of $472.05-$486.77 for about $4.54 million, exercised 19,000 options at $117.76, and left 324,443 shares held.
SEC4 0001106578-26-000152litigation_outcomeThe US District Court for the District of Delaware ruled that Liquidia's Yutrepia (treprostinil) inhalation powder infringes claims 1 and 14 of United Therapeutics' '327 patent covering inhaled treprostinil for PH-ILD, while the four other asserted claims were invalidated; the parties have one week to submit a proposed judgment with remedies.
notable_investor_commentRBC Capital Markets analyst Lisa Walter said the Delaware court ruling 'significantly clouds the path' for Liquidia's Yutrepia to compete, and Leerink Partners analysts called the decision essentially a win for United Therapeutics confirming Yutrepia infringes a valid UTHR patent.
peer_disclosureLiquidia CEO Roger Jeffs said the company disagrees with the Delaware court's ruling on claims 1 and 14, will pursue appellate options, and intends to submit a supplement to Yutrepia's NDA asking the FDA to remove the PH-ILD indication from its label.
insider_saleUnited Therapeutics CEO and Chair Martine A. Rothblatt reported multiple Form 4 sales of 9,500 shares each in September 2026, worth roughly $4.6-4.8 million per transaction, while still controlling about 668,700 shares.
trading_haltTrading in Liquidia Corporation shares was halted and then fell sharply after the US District Court for the District of Delaware ruled its Yutrepia infringed United Therapeutics' '327 patent.
regulatory_approvalThe FDA accepted United Therapeutics' supplemental new drug application for nebulized Tyvaso in idiopathic pulmonary fibrosis, with a review decision expected around late April 2027, backed by the Phase 3 TETON-1 and TETON-2 trials.
litigation_outcomeUnited Therapeutics said it believes it is entitled to an order instructing the FDA to withdraw approval of Liquidia's Yutrepia NDA under 35 U.S.C. §271(e)(4)(A), which could remove Yutrepia from the U.S. market until labeling omits the PH-ILD indication, and will seek monetary damages including a royalty on past Yutrepia sales.
buybackUnited Therapeutics entered a $477.6 million accelerated share repurchase agreement with Citibank, the final tranche of its $2 billion buyback authorization, with final settlement expected in Q4 2026.